Drug
Lexiscan
Lexiscan is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
NCT05583721
completedphase_2
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
NCT03103061
completedphase_1
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
NCT01085201
Clinical Trials (3)
Showing 3 of 3 trials
NCT05583721Phase 2
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
NCT03103061Phase 2
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
NCT01085201Phase 1
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3